| Similar Articles |
|---|
 |
CIO
April 15, 2006
Stephanie Overby |
The Three- or Four-Year Itch To succeed, relationships require love and attention. That's why CIOs - especially mid-market CIOs with limited resources - should factor in the costs of hand-holding when going offshore.   |
CIO
June 14, 2011
Bill Bulkeley |
What CFOs Need to Hear about Cloud Computing and Consumer IT Cloud computing and consumerization of IT change how you buy and budget for technology. Here's how to talk about it with the CFO. |
CIO
October 1, 2003
Jack Keen |
Wanted: Metric Skeptics Accepting vague or irrelevant numbers for project value can lead to bad IT spending decisions. |
CFO
June 1, 2007
Scott Leibs |
Measuring Up Many companies still struggle to use metrics effectively. It may be that fresh thinking is what really counts. |
Pharmaceutical Executive
September 1, 2011 |
Pharm Exec's 10th Annual Industry Audit A survey of the landscape of pharma financials over the past year, and a look at which companies rode the wave to the top of the industry in delivering value to shareholders. |
IndustryWeek
May 1, 2008
John Teresko |
Seven Emerging Trends in R&D Metrics More companies tracking 'true performance metrics'. |
CRM
May 10, 2013
Syed Hasan |
Choose a Winning Combination of Customer Experience Metrics Improve customer loyalty with the right mix of customer experience management (CEM) solutions. |
CIO
September 1, 2003
Christopher Koch |
Backlash As a growing number of IT jobs move overseas, some CIOs and economists prophesy a political storm against offshore outsourcing. |
Pharmaceutical Executive
September 1, 2010 |
Pharm Exec's Ninth Annual Industry Audit Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond. |
Pharmaceutical Executive
September 1, 2012
Bill Trombetta |
Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players. |
Pharmaceutical Executive
September 1, 2014
Bill Trombetta |
13th Annual Industry Audit After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players. |
